Genentech’s Activase, a recombinant tissue plasminogen activator is approved for the management of acute ischemic stroke in adults.
Through this agreement, the companies will collaborate and Genentech will provide Activase in-servicing and education to hospitals that have InTouch’s Remote Presence telestroke capabilities.
This service is intended to benefit InTouch’s telestroke customers by ensuring that a facility’s emergency department staff receives timely training after the installation of a Remote Presence telestroke system on the proper use of Activase.
Yulun Wang, chairman and CEO of InTouch Technologies, said: “I am very pleased to announce this agreement with Genentech. Stroke is a leading cause of death and permanent disability in the US and we hope that efforts such as this collaboration will continue to advance the standard of stroke care, particularly in geographically remote areas.”